Related Experiment Video
Updated: Jul 11, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model
Melissa A Barber1, Tong Zhang, Bethany A Gagne
1Department of Microbiology and Immunology, Dartmouth Medical School, 6W Borwell Bldg, Lebanon, NH 03756, USA.
Background:
NK cell activity is regulated in part by inhibitory receptors that bind to MHC class I molecules. It is possible to enhance NK cell cytotoxicity against tumor cells by preventing the interaction of these inhibitory receptors with their MHC class I ligands.
Results:
In this study, we determined that Ly49G2 is an inhibitory receptor in AKR mice for self-MHC class I, and AKR Ly49G2 has an identical sequence to BALB/c Ly49G2. Blockade of Ly49G2 receptors in vivo resulted in decreased growth of BW-Sp3 lymphoma cells when the tumor cells were given i.v. but not when the tumor cells were inoculated into the flank forming a solid tumor. However, NK cells were involved in inhibiting the growth of BW-Sp3 tumor cells in the flank.
Conclusion:
These data demonstrate that the effectiveness of inhibitory receptor blockade depends upon the tissue location of the tumor cells.
